Results 181 to 190 of about 113,188 (264)
Fit cells, fertile ground: Immunometabolic programming and bone marrow niche support in durable CAR T cell response in leukemia. [PDF]
Wang X, Goldberg L.
europepmc +1 more source
ABSTRACT Background Cell therapy, particularly those utilizing mesenchymal stem/stromal cells (MSCs), is gaining traction as a therapeutic option for regenerative treatment in patients with limited therapeutic options. Although the safety of MSC‐based interventions is well established, uncertainties remain regarding how genetic abnormalities and ...
Marzena Zychowicz +12 more
wiley +1 more source
CD19 CAR T cells for B-ALL with EMD. [PDF]
Llaurador Caraballo G, Steffin D.
europepmc +1 more source
A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz +17 more
wiley +1 more source
Exploring current evidence on bispecific CAR-T cell therapy for acute leukemias: a systematic review. [PDF]
Husodho GVP +4 more
europepmc +1 more source
Cirrhosis patients with untreated HBV in Ethiopia exhibit a distinct immune profile marked by depletion of NK cells, B cells, and T cells, alongside an expanded CD38+HLA‐DR+ CD8 T‐cell population. ABSTRACT Background and Aims The immune cell phenotype of African patients living with chronic hepatitis B virus (HBV) infection is rarely described, despite
Julia MacLeod +9 more
wiley +1 more source
BATF3 regulates differentiation of CD8<sup>+</sup> T lymphocytes and memory differentiation program. [PDF]
Umemura K +10 more
europepmc +1 more source
Summary To assess the cost‐effectiveness of blinatumomab plus chemotherapy for paediatric patients from Hong Kong public healthcare provider's perspective, a 10‐year Markov model was designed to simulate outcomes in paediatric patients with newly diagnosed standard‐risk B‐cell ALL at: (1) average risk and (2) high risk of relapse.
Mingjun Rui +7 more
wiley +1 more source
Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function. [PDF]
Dietze KA +18 more
europepmc +1 more source

